Pharmacogenetics in Latin American populations: Regulatory aspects, application to herbal medicine, cardiovascular and psychiatric disorders

Drug Metabolism and Drug Interactions

Volume 27, Issue 1, 1 March 2012, Pages 57-60

Rodeiro, I.^abm, 

Remírez-Figueredo, D.^ac, 

García-Mesa, M.^d, 

Dorado, P.^ae, 

Llerena, A.^ae , 

Moya, G.E.^f, 

Ferrero, V.^f, 

Tarazona-Santos, E.^gh, 

Fiedler, J.ⁱ, 

Herrera, L.ⁱ, 

Rojas-Ponce, R.^j, 

Sarmiento-Sánchez, A.P.^k, 

Borbón-Orejuela, A.^k, 

Barrantes, R.^l, 

Jiménez-Arce, G.^l, 

Céspedes, C.^l, 

Álvarez, M.ⁿ, 

Pérez, B.ⁿ, 

Calzadilla, L.^o, 

Delgado, R.^p, 

Remirez, D.^q, 

Terán, E.^rs, 

Heras, N.^s, 

Beltrán, L.^s, 

Hernández, F.^t, 

Doredo, P.^u, 

Peñas-Lledó, E.M.^u, 

Cobaleda, J.^u, 

González-Naranjo, M.E.^u, 

De Andrés, F.^u, 

Ortiz-López, R.^v, 

Rojas-Martínez, A.^v, 

Garza-Ocañas, L.^v, 

Pérez-Páramo, Y.X.^v, 

López-López, M.^w, 

Ortega-Vázquez, A.^w, 

Alonso-Vilatela, E.^x, 

Monroy-Jaramillo, N.^x, 

Vázquez, T.C.^x, 

Yescas-Gómez, P.^x, 

Ochoa-Morales, A.^x, 

Sosa-Macías, M.G.^y, 

Galaviz-Hernández, C.^y, 

Lares, I.^y, 

Lazalde, B.^y, 

Ramirez-Roa, R.^z, 

Grazina, M.^aa, 

Estévez-Carrizo, F.E.^ab, 

González-Vacarezza, N.^ab

 

Hide additional authors

^a  Ibero American Network of Pharmacogenetics and Pharmacogenomics (RIBEF), Havana, Cuba
^b  Centre of Marine Bioproducts (CEBIMAR), Havana, Cuba
^c  National Centre for State Quality Control of Drugs (CECMED), Havana, Cuba

View additional affiliations

View references (16)

Abstract

Meeting report of the " Second Symposium on Pharmacology of Cytochrome P450 and Transporters " organized by the Cuban Society of Pharmacology in collaboration with the European Society of Pharmacogenetics and Theranostics (ESPT) and the Ibero-American Network of Pharmacogenetics and Pharmacogenomics (www.ribef.com). The Symposium covered different topics on pharmacogenetics and its clinical implications, focusing on Latin-American populations. The activities of the ESPT were also presented and discussed. The topics addressed were regulatory aspects, the use of pharmacogenetics in pre-clinical research, herbal medicine, and natural products, ending with a discussion about translation into clinical practice, specifically for cardiovascular disorders and psychiatry. Finally, the implication for population diversity in Latin America was also discussed. The RIBEF initiative represents a promising step towards the inclusion of Latin American populations among those to benefit from the implementation of pharmacogenetics in clinical practice. Among current RIBEF activities, the CEIBA.FP Consortium aims to study the variability of pheno-and genotypes in Hispanics that are relevant to pharmacogenetics. For this purpose, populations from Mexico, Cuba, Nicaragua, Costa Rica, Ecuador, Colombia, Brasil, Perú, Chile, Uruguay, Argentina, Portugal, and Spain are currently being studied. The meeting's main conclusion was that population pharmacogenetic studies as well as academic clinical trials might need to be conducted in the different geographic locations/countries. This is important in order to improve drug safety, dosage recommendations, and pharmacovigilance programs, because environmental and ethnic factors vary across locations. © 2012 by Walter de Gruyter Berlin Boston.

Author keywords

cytochrome P450; Hispanics; Latin America; pharmacogenetics

Indexed keywords

EMTREE drug terms: cyclosporin; cytochrome P450; digoxin; drug metabolite; glucuronosyltransferase; glycoprotein P; herbaceous agent; indinavir; irinotecan; Mangifera indica extract; natural product; neuroleptic agent; oral contraceptive agent; serotonin uptake inhibitor; tricyclic antidepressant agent

EMTREE medical terms: Argentina; Brazil; cardiovascular disease; Chile; clinical practice; clinical research; clinical trial (topic); Colombia; conference paper; Costa Rica; Cuba; drug blood level; drug efficacy; drug response; drug safety; drug screening; drug surveillance program; eating disorder; Ecuador; environmental exposure; environmental factor; enzyme induction; ethnicity; genetic polymorphism; genotype; geography; geriatric patient; herbal medicine; Hispanic; human; Hypericum perforatum; legal aspect; medical society; mental disease; Nicaragua; Peru; pharmacogenetics; pharmacogenomics; phenotype; population research; Portugal; protein expression; risk benefit analysis; South and Central America; Spain; suicide; symposium; Uruguay

MeSH: Cardiovascular Diseases; Herbal Medicine; Humans; Latin America; Mental Disorders; Pharmacogenetics
Medline is the source for the MeSH terms of this document.

Chemicals and CAS Registry Numbers: cyclosporin, 79217-60-0; cytochrome P450, 9035-51-2; digoxin, 20830-75-5, 57285-89-9; glucuronosyltransferase, 37329-64-9, 9030-08-4; indinavir, 150378-17-9, 157810-81-6, 180683-37-8; irinotecan, 100286-90-6

ISSN: 07925077 CODEN: DMDIESource Type: Journal Original language: English

DOI: 10.1515/dmdi-2012-0006 PubMed ID: 22718626Document Type: Conference Paper

References (16)

View in search results format

• Page
• • Export |
  • Print |
  • E-mail |
  • Create bibliography

• 
  1

  Goodsaid, F., Frueh, F.W.
  

  Implementing the U.S. FDA guidance on pharmacogenomic data submissions
  (2007) Environmental and Molecular Mutagenesis, 48 (5), pp. 354-358. Cited 42 times.
  doi: 10.1002/em.20294
  

  • View at Publisher
• 
  2

  Lesko, L.J., Woodcock, J.
  

  Pharmacogenomic-guided drug development: Regulatory perspective
  (2002) Pharmacogenomics Journal, 2 (1), pp. 20-24. Cited 81 times.
  doi: 10.1038/sj.tpj.6500046
  

  • View at Publisher
• 
  3

  Shah, R.R.
  

  Can pharmacogenetics help rescue drugs withdrawn from the market?
  (2006) Pharmacogenomics, 7 (6), pp. 889-908. Cited 123 times.
  http://www.futuremedicine.com/doi/full/10.2217/14622416.7.6.889
  doi: 10.2217/14622416.7.6.889
  

  • View at Publisher
• 
  4

  Lambert, J.D., Sang, S., Lu, A.Y.H., Yang, C.S.
  

  Metabolism of dietary polyphenols and possible interactions with drugs
  (2007) Current Drug Metabolism, 8 (5), pp. 499-507. Cited 40 times.
  http://www.ingentaconnect.com/content/ben/cdm/2007/00000008/00000005/art00008
  doi: 10.2174/138920007780866870
  

  • View at Publisher
• 
  5

  Galli, F.
  

  Interactions of polyphenolic compounds with drug disposition and metabolism
  (2007) Current Drug Metabolism, 8 (8), pp. 830-838. Cited 15 times.
  http://www.ingentaconnect.com/content/ben/cdm/2007/00000008/00000008/art00010
  doi: 10.2174/138920007782798180
  

  • View at Publisher
• 
  6

  Rodeiro, I., Donato, M.T., Lahoz, A., González-Lavaut, J.A., Laguna, A., Castell, J.V., Delgado, R., (...), Gómez-Lechón, M.J.
  

  Modulation of P450 enzymes by Cuban natural products rich in polyphenolic compounds in rat hepatocytes
  (2008) Chemico-Biological Interactions, 172 (1), pp. 1-10. Cited 25 times.
  doi: 10.1016/j.cbi.2007.10.004
  

  • View at Publisher
• 
  7

  Rodeiro, I., Donato, M.T., Lahoz, A., Garrido, G., Delgado, R., Gómez-Lechón, M.J.
  

  Interactions of polyphenols with the P450 system: Possible implications on human therapeutics
  (2008) Mini-Reviews in Medicinal Chemistry, 8 (2), pp. 97-106. Cited 33 times.
  http://www.ingentaconnect.com/content/ben/mrmc/2008/00000008/00000002/art00001
  doi: 10.2174/138955708783498131
  

  • View at Publisher
• 
  8

  Postuła, M., Tarchalska-Kryńska, B., Filipiak, K.J., Kosior, D., Serafin, A., Huczek, Z., Opolski, G.
  

  Factors responsible for "aspirin resistance" - Can we identify them?
  (2010) Kardiologia Polska, 68 (4), pp. 403-411. Cited 13 times.
  http://www.kardiologiapolska.pl/en/darmowy_pdf.phtml?indeks=92&indeks_art=2360
  

  • View at Publisher
• 
  9

  Śpiewak, M., Małek, Ł.A., Kostrzewa, G., Kisiel, B., Serafin, A., Filipiak, K.J., Płoski, R., (...), Opolski, G.
  

  Influence of C3435T multidrug resistance gene-1 (MDR-1) polymorphism on platelet reactivity and prognosis in patients with acute coronary syndromes
  (2009) Kardiologia Polska, 67 (8), pp. 827-834. Cited 19 times.
  http://www.termedia.pl/showpdf.php?article_id=13112&filename=Influence.pdf&priority=1
  

  • View at Publisher
• 
  10

  Kasotakis, G., Pipinos, I.I., Lynch, T.G.
  

  Current evidence and clinical implications of aspirin resistance
  (2009) Journal of Vascular Surgery, 50 (6), pp. 1500-1510. Cited 32 times.
  doi: 10.1016/j.jvs.2009.06.023
  

  • View at Publisher
• 
  11

  Peñas-LLedó, E.M., Dorado, P., Pacheco, R., González, I., Llerena, A.
  

  Relation between CYP2D6 genotype, personality, neurocognition and overall psychopathology in healthy volunteers
  (2009) Pharmacogenomics, 10 (7), pp. 1111-1120. Cited 24 times.
  http://www.futuremedicine.com/doi/pdf/10.2217/pgs.09.75
  doi: 10.2217/pgs.09.75
  

  • View at Publisher
• 
  12

  Peñas-Lledó, E.M., Dorado, P., Agüera, Z., Gratacós, M., Estivill, X., Fernández-Aranda, F., Llerena, A.
  

  High risk of lifetime history of suicide attempts among CYP2D6 ultrarapid metabolizers with eating disorders
  (2011) Molecular Psychiatry, 16 (7), pp. 691-692. Cited 25 times.
  doi: 10.1038/mp.2011.5
  

  • View at Publisher
• 
  13

  Peñas-Lledó, E.M., Dorado, P., Agüera, Z., Gratacós, M., Estivill, X., Fernández-Aranda, F.
  CYP2D6 polymorphism in patients with eating disorders
  (2010) Pharmacogenomics J, 28. Cited 2 times.
  Sep Epub ahead of print
  

  •  
• 
  14

  Llerena, A., Dorado, P., Ramírez, R., González, I., Alvarez, M., Peñas-Lledó, E.M.
  CYP2D6 genotype and debrisoquine hydroxyla-tion phenotype in Cubans and Nicaraguans
  (2010) Pharmacogenomics J, 7. Cited 5 times.
  Dec Epub ahead of print
  

  •  
• 
  15

  Dorado, P., Sosa-Macias, M.G., Peñas-Lledó, E.M., Alanis-Bãuelos, R.E., Wong, M.-L., Licinio, J., Lares-Asseff, I., (...), Llerena, A.
  

  CYP2C9 allele frequency differences between populations of Mexican-Mestizo, Mexican-Tepehuano, and Spaniards
  (2011) Pharmacogenomics Journal, 11 (2), pp. 108-112. Cited 22 times.
  doi: 10.1038/tpj.2010.29
  

  • View at Publisher
• 
  16

  Dorado, P., Heras, N., MacHín, E., Hernández, F., Teran, E., Llerena, A.
  CYP2D6 genotype and dextromethorphan hydroxylation phenotype in an Ecuadorian population
  (2011) Eur J Clin Pharmacol, 15.
  Nov Epub ahead of print
  

  •  

  Llerena, A.; Clinical Research Centre (CICAB), University of Extremadura Medical School, Hospital Infanta Cristina, 06080 Badajoz, Spain; email:allerena@unex.es
© Copyright 2012 Elsevier B.V., All rights reserved. © MEDLINE® is the source for the MeSH terms of this document.